| Median age (IQR) |
69.6 |
(61.3, 74.8) |
72.6 |
(63.1, 79.6) |
0.366 |
| No. gender (%): |
|
|
|
|
0.05 |
| F |
22 |
(11.1) |
19 |
(19.4) |
|
| M |
177 |
(88.9) |
79 |
(80.6) |
|
| No. race (%): |
|
|
|
|
0.829 |
| Caucasian |
180 |
(90.5) |
86 |
(87.0) |
|
| African-American |
5 |
(2.5) |
4 |
(4.1) |
|
| Hispanic |
13 |
(6.5) |
7 |
(7.1) |
|
| Asian |
1 |
(0.5) |
1 |
(1.0) |
|
| No. smoking history (%): |
|
|
|
|
0.557 |
| Never |
43 |
(21.9) |
23 |
(23.5) |
|
| Former |
115 |
(58.7) |
61 |
(62.2) |
|
| Current |
38 |
(19.4) |
14 |
(14.3) |
|
| No. body mass index (kg/m2) (%): |
|
|
|
|
0.150 |
| Less than 25.0 |
47 |
(24.9) |
38 |
(35.5) |
|
| 25.0–29.9 |
84 |
(44.4) |
41 |
(38.3) |
|
| 30.0–34.9 |
43 |
(22.8) |
17 |
(15.9) |
|
| 35.0 or Greater |
15 |
(7.9) |
11 |
(10.3) |
|
| No. prior intravesical treatment (%) |
46 |
(23.1) |
18 |
(18.4) |
0.349 |
| No. concomitant carcinoma in situ (%) |
52 |
(26.1) |
28 |
(28.6) |
0.656 |
| No. clinical tumor stage (%): |
|
|
|
|
<0.001 |
| cT1
|
0 |
(0) |
29 |
(29.6) |
|
| cT2
|
199 |
(100.0) |
50 |
(51.0) |
|
| cT3b
|
0 |
|
14 |
(14.3) |
|
| cT4a
|
0 |
|
5 |
(5.1) |
|
| Median mos from TUR to RC (IQR) |
1.5 |
(1.0, 2.4) |
1.4 |
(0.9, 1.9) |
0.321 |
| No. preop hemoglobin (%): |
|
|
|
|
0.063 |
| 12-16 (female) or 14-18 (male) |
104 |
(52.3) |
42 |
(42.0) |
|
| Less than 12 (female) or less than 14 (male) |
95 |
(47.7) |
58 |
(59.2) |
|
| Median pre-RC laboratory values (IQR): |
|
|
|
|
|
| Glomerular filtration rate |
74.5 |
(62, 83.5) |
69 |
(50, 85) |
0.585 |
| Platelet count |
229 |
(193, 277) |
248 |
(210, 326) |
0.161 |
| Creatinine |
1.0 |
(0.9, 1.3) |
1.0 |
(0.9, 1.4) |
0.928 |
| Albumin |
4.1 |
(4.0, 4.4) |
4.1 |
(3.8, 4.4) |
0.530 |
| Calcium |
9.1 |
(8.9, 9.4) |
9.1 |
(8.8, 9.4) |
0.988 |
| Alkaline phosphatase |
77.5 |
(66, 89) |
77 |
(63, 97) |
0.960 |
| Lactate dehydrogenase |
447.5 |
(397.5, 514) |
432 |
(393, 505) |
0.461 |
| No. history of malignancy (%) |
22 |
(11.1) |
18 |
(18.4) |
0.090 |
